Access to the PPM Journal and newsletters is FREE for clinicians.

All Pumps Articles

Trial will examine SynchroMed II as an opioid alternative for chronic back pain.
FDA has approved Medtronic's myPTM, which works with the company's SynchroMed II intrathecal drug delivery system.
An overview of current approaches in intrathecal drug delivery for cancer pain management.
Opioid intrathecal therapy offers the advantage of delivering medication directly to the dorsal horn of the spinal cord—increasing potency and reducing the systemic exposure—thus reducing side effects.
A survey of the "science" behind exclusionary psychological assessment finds that supporting empirical data is virtually non-existent and may be unduly limiting access to those patients for whom this treatment represents their only chance for comfort and a reasonable quality of life.
Administering a continuous lumbar epidural infusion of corticosteroid and normal saline via an indwelling epidural catheter/infusion pump over a 3-day period offers a minimally-invasive option for treatment of lumbar radiculopathy.
A trialing protocol before initiation of long-term ziconotide intrathecal therapy is presented.
Retrospective case studies in intrathecal drug therapy patients with severe chronic pain demonstrate the safety and efficacy of ziconotide in improving pain management while reducing (or even halting) oral and intrathecal narcotic pain medications.
Practical Issues of Reimbursement for IT Drug Delivery: The Ziconotide Model
Are Intrathecal Therapy Trials Necessary?
Despite significant, positive advances in opioid formulations ranging from long-acting tablets to lollipops, the most potent way to administer opioids is by the intrathecal route. Editor of Practical Pain Management discusses the underutilization of intrathetcal treatments (such as spinal pumps).
close X